Skip to main content

Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction.

Publication ,  Journal Article
Turer, AT; Mahaffey, KW; Gallup, D; Weaver, WD; Christenson, RH; Every, NR; Ohman, EM
Published in: Curr Control Trials Cardiovasc Med
August 23, 2005

BACKGROUND: Cardiac biomarkers are routinely obtained in the setting of suspected myocardial ischemia and infarction. Evidence suggests these markers may correlate with functional and clinical outcomes, but the strength of this correlation is unclear. The relationship between enzyme measures of myocardial necrosis and left ventricular performance and adverse clinical outcomes were explored. METHODS: Creatine kinase (CK) and CK-MB data were analyzed, as were left ventricular ejection fraction (LVEF) by angiogram, and infarct size by single-photon emission computed tomography (SPECT) imaging in patients in 2 trials: Prompt Reperfusion In Myocardial-infarction Evolution (PRIME), and Efegatran and Streptokinase to Canalize Arteries Like Accelerated Tissue plasminogen activator (ESCALAT). Both trials evaluated efegatran combined with thrombolysis for treating acute ST-segment elevation myocardial infarction (STEMI). RESULTS: Peak CK and CK area-under-the-curve (AUC) correlated significantly with SPECT-determined infarct size 5 to 10 days after enrollment. Peak CK had a statistically significant correlation with LVEF, but CK-AUC and LVEF correlation were less robust. Statistically significant correlations exist between SPECT-determined infarct size and peak CK-MB and CK-MB AUC. However, there was no correlation with LVEF for peak CK-MB and CK-MB AUC. The combined outcome of congestive heart failure and death were significantly associated with CK AUC, CK-MB AUC, peak CK, and peak CK-MB measurements. CONCLUSION: Peak CK and CK-MB values and AUC calculations have significant correlation with functional outcomes (LVEF- and SPECT-determined infarct size) and death or CHF outcomes in the setting of STEMI. Cardiac biomarkers provide prognostic information and may serve as valid endpoint measurements for phase II clinical trials.

Duke Scholars

Published In

Curr Control Trials Cardiovasc Med

DOI

EISSN

1468-6694

Publication Date

August 23, 2005

Volume

6

Issue

1

Start / End Page

12

Location

England

Related Subject Headings

  • General & Internal Medicine
  • Cardiovascular System & Hematology
  • 4203 Health services and systems
  • 4202 Epidemiology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Turer, A. T., Mahaffey, K. W., Gallup, D., Weaver, W. D., Christenson, R. H., Every, N. R., & Ohman, E. M. (2005). Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction. Curr Control Trials Cardiovasc Med, 6(1), 12. https://doi.org/10.1186/1468-6708-6-12
Turer, Aslan T., Kenneth W. Mahaffey, Dianne Gallup, W Douglas Weaver, Robert H. Christenson, Nathan R. Every, and E Magnus Ohman. “Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction.Curr Control Trials Cardiovasc Med 6, no. 1 (August 23, 2005): 12. https://doi.org/10.1186/1468-6708-6-12.
Turer AT, Mahaffey KW, Gallup D, Weaver WD, Christenson RH, Every NR, et al. Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction. Curr Control Trials Cardiovasc Med. 2005 Aug 23;6(1):12.
Turer, Aslan T., et al. “Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction.Curr Control Trials Cardiovasc Med, vol. 6, no. 1, Aug. 2005, p. 12. Pubmed, doi:10.1186/1468-6708-6-12.
Turer AT, Mahaffey KW, Gallup D, Weaver WD, Christenson RH, Every NR, Ohman EM. Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction. Curr Control Trials Cardiovasc Med. 2005 Aug 23;6(1):12.

Published In

Curr Control Trials Cardiovasc Med

DOI

EISSN

1468-6694

Publication Date

August 23, 2005

Volume

6

Issue

1

Start / End Page

12

Location

England

Related Subject Headings

  • General & Internal Medicine
  • Cardiovascular System & Hematology
  • 4203 Health services and systems
  • 4202 Epidemiology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology